Avicanna introduces medical cannabis education online portal for health care professionals
Established with the support of experts in the fields of pain management, neurology, and dermatology, the portal is designed to address potential gaps in knowledge and training related to the potential use of cannabis in a medical context
October 19, 2022 By Grow Opportunity Staff
(Globe Newswire) Toronto — Avicanna Inc., an international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce that it has launched its medical cannabis education portal, ”Avicenna Academy,” a no-cost resource and medical education portal for Health Care Professionals (“HCPs”).
The medical education portal is designed to support HCPs through education and practical information with respect to the potential use of medical cannabis, with a view towards expanding access as well as measuring patient outcomes.
The Avicenna Academy is designed to address the potential gaps in understanding cannabinoid-based products while making available resources and information which may be tools for the medical community. Towards that goal, Avicanna’s medical team has combined its research and development expertise with cannabinoid formulations utilizing advanced drug delivery systems.
Practical experience in delivering RHO PhytoTM medical cannabis products through established medical portals, pharmacies, major hospitals both in Canada and international markets has allowed Avicanna to develop various educational resources such as downloadable guides, online modules, and access to discussions with key opinion leaders across a range of medical specialities.
The portal currently includes a range of resources including HCP guidelines and supporting information regarding medical authorization documentation for patients in Canada.
The Avicenna Academy looks towards expanding offerings in the portal that are reflective of on-going research in the field. Access to the Avicenna Academy will be offered at no cost for HCPs to support necessary education and training.
The company is actively collaborating with the medical community to improve this current initiative and is also working toward building indication-specific modules in collaboration with Canadian and international key opinion leaders and experts in their respective fields.
“We are excited about the launch of this Platform as a resource that facilitates information and education to potentially improve patient outcomes and foster further collaboration with the medical community.” — Aras Azadian, CEO, Avicanna Inc.
Print this page
- LOVE Pharma’s update on launch of sponsored psilocybin trials at John Hopkins University
- Key features to look for when purchasing LEDs, part two